NanoMosaic Installs Wide Dynamic Range Proteomic Beta System at The New York Stem Cell Foundation Research Institute (NYSCF)
NEW YORK, April 6, 2021 /PRNewswire/ -- NanoMosaic, the pioneer and leader in nanoneedle (MosaicNeedle™) detection for proteomics and genomics, has installed its end-user fully customizable, nanoneedle proteomic beta system, "Tessie™," at its second test site, the New York Stem Cell Foundation Research Institute (NYSCF). TessieTM, is able to achieve seven orders of dynamic range interrogation at a competitive, lower price per-protein than commercially available systems. NYSCF, a global leader in translational stem cell research, will utilize the platform to further understand the proteomic profiles at various stages of stem cell differentiation.
Following the successful beta program at the Massachusetts General Hospital, where the Tessie™ system is now being utilized to run clinical samples for the development of a diagnostic test for post operative-delirium, this marks the second system install that the company has publicly announced. NanoMoasic will team with leaders in a number of cutting-edge disciplines to leverage the advantages of the system in order to unlock the universe of undiscovered biomarkers across a broad range of indications.
"NYSCF is excited to be working with NanoMosaic and to be the second test site for the Tessie™ system," said Susan L. Solomon, NYSCF Founder and CEO. "Our mission is to accelerate new treatments and cures for patients, and this new system will allow us to further enhance our understanding of stem cell biology and augment our sample processing and discovery analysis," Ms. Solomon concluded.
"We are thrilled and honored to be working with Ms. Solomon and the world class team she has built at NYSCF," stated John Boyce, Co-Founder, President and CEO of NanoMosaic as well as Co-Founder of Tiger Gene. "The goals of NYSCF to accelerate the field of stem cell research and to create derived therapeutics from those efforts, align with NanoMosaic's mission to understand proteomics to treat and prevent disease," Boyce continued. "The company is looking forward to the results from this beta program and the potential future change in medicine that a powerful NYSCF/NanoMosaic partnership may lead to," Boyce concluded.
About the New York Stem Cell Foundation Research Institute
About Tiger Gene L.L.C.
View original content to download multimedia:http://www.prnewswire.com/news-releases/nanomosaic-installs-wide-dynamic-range-proteomic-beta-system-at-the-new-york-stem-cell-foundation-research-institute-nyscf-301262377.html